GlassScriptPhysician profile
Nitin Thapar
NPI 1780927483
$215,657.91
in general payments reported to CMS, 2019-2025
38 companies · $44K in 2025
The $44K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $27K · 2021: $33K · 2022: $20K · 2023: $59K · 2024: $18K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Food and Beverage: $8,329 · Travel and Lodging: $6,843 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $106,650.00 |
| Food and Beverage | $8,329.06 |
| Travel and Lodging | $6,842.94 |
| Education | $180.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $131,299.60 | 2021-2025 | Vraylar |
| Allergan, INC. | $35,057.53 | 2019-2020 | |
| Alkermes, INC. | $19,715.79 | 2019-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $11,178.50 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $10,714.08 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $867.23 | 2019-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $788.65 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $608.98 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $595.29 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $582.87 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $569.88 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $561.37 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Neurocrine Biosciences, INC. | $509.96 | 2019-2025 | Ingrezza |
| Indivior INC. | $289.55 | 2019-2023 | Perseris |
| Ironshore Pharmaceuticals INC. | $229.30 | 2019-2024 | Jornay Pm |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $222.02 | 2021-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $220.47 | 2019 | |
| Tris Pharma INC | $218.01 | 2022-2025 | Dyanavel Xr |
| Orexo US, INC. | $153.99 | 2019-2024 | Zubsolv |
| Bausch Health US, LLC | $149.04 | 2019-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $138.83 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $123.68 | 2019-2021 | |
| Eisai INC. | $112.14 | 2020-2025 | |
| Neos Therapeutics, LP | $103.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $91.89 | 2022-2024 | Quviviq |
| Adlon Therapeutics L.P. | $90.44 | 2019-2020 | |
| Noven Therapeutics, LLC | $77.78 | 2022-2025 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $73.66 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $72.23 | 2019-2025 | Relexxii |
| Braeburn INC. | $66.45 | 2024-2025 | Brixadi |
| Almatica Pharma LLC | $41.54 | 2022-2025 | Loreev Xr |
| Uswm, LLC | $30.96 | 2023 | Zimhi, Lucemyra |
| Avanir Pharmaceuticals, INC. | $20.76 | 2019 | |
| Luye Pharma (USA) LTD. | $19.50 | 2025 | Erzofri Extended-Release |
| Livanova USA, INC. | $18.96 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Biogen, INC. | $16.98 | 2024 | |
| Acadia Pharmaceuticals INC | $14.45 | 2019 | |
| Neuronetics, INC. | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Thapar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.